Fixed combination therapies in COPD--effect on quality of life.
Chronic obstructive pulmonary disease (COPD) represents a major global cause of disability and death. COPD is currently the fourth most common global cause of death and also exerts an enormous toll on patients quality of life. The present database analysis aimed to identify clinical trials using fixed combination therapies that have assessed the impact on the patients quality of life. Within the different studies, questionnaires including the George's Respiratory Questionnaire (SGRQ) the Chronic Respiratory Disease Questionnaire (CRDQ) and the Clinical COPD Questionnaire (CCQ) were used and differing results in quality of life were obtained when combination therapies such as fluticasone/salmeterol or fluticasone/salmeterol were compared with monotherapies. While there were some differences in favor of combination therapies reported when the combination therapy was compared to inhaled steroid monotherapy there were no consistent differences when combination therapies were compared to bronchodilator monotherapies. Future trials will lead to a proof-of-principle stage concerning the use of combination therapies.
Groneberg-Kloft
Beatrix
B
Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Fischer
Axel
A
Welte
Tobias
T
D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005858:Germany; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000628:therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires